Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor

Annals of the Rheumatic Diseases

Volumn 69, Issue 4, 2010, Pages 741-746

  Hashizume, Misato ^a   Yoshida, Hiroto ^a   Koike, Nobuo ^a   Suzuki, Miho ^a   Mihara, Masahiko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; LIPID BLOOD LEVEL; LIPID METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELLS, CULTURED; CHOLESTEROL; FEMALE; HUMANS; INTERLEUKIN-6; LIPID METABOLISM; LIPIDS; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-6; RECEPTORS, LDL; RECOMBINANT PROTEINS; RNA, MESSENGER; TRIGLYCERIDES; UP-REGULATION;

EID: 77950335656     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.104844     Document Type: Article

References (22)

1. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2004;50:1761-1769
2. Saiki O, Takao R, Naruse Y, et al. Infliximab but not methotrexate induces extrahigh levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Rheumatol 2007;34:1997-2004.
3. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis - the Third National Health and Nutrition Examination Survey. J Rheumatol 2005;32:2311-2316
4. Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002;113:188-193
5. Memon RA, Grunfeld C, Moser AH, et al. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993;132:2246-2253
6. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304-311
7. Wallenius V, Wallenius K, Ahrén B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75-79
8. Espirito Santo SM, Rensen PC, Goudriaan JR, et al. Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. J Lipid Res 2005;46:1097-1102
9. Tacken PJ, Teusink B, Jong MC, et al. LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice. J Lipid Res 2000;41:2055-2062
10. Takahashi M, Takahashi S, Suzuki C, et al. Interleukin-1beta attenuates beta-very low-density lipoprotein uptake and its receptor expression in vascular smooth muscle cells. J Mol Cell Cardiol 2005;38:637-646
11. Uchiyama Y, Yoshida H, Koike N, et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol 2008;8:1595-1601
12. Tacken PJ, Hofker MH, Havekes LM, et al. Living up to a name: the role of the VLDL receptor in lipid metabolism. Curr Opin Lipidol 2001; 12:275-279
13. Kamataki A, Takahashi S, Masamura K, et al. Remnant lipoprotein particles are taken up into myocardium through VLDL receptor - a possible mechanism for cardiac fatty acid metabolism. Biochem Biophys Res Commun 2002; 293:1007-1013
14. Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990;63:1149-1157
15. Kreuter R, Soutar AK, Wade DP. Transcription factors CCAAT/enhancer- binding protein beta and nuclear factor-Y bind to discrete regulatory elements in the very low density lipoprotein receptor promoter. J Lipid Res 1999;40:376-386
16. Poli V, Cortese R. Interleukin 6 induces a liver-specific nuclear protein that binds to the promoter of acute-phase genes. Proc Natl Acad Sci USA 1989;86:8202-8206
17. MacDougald OA, Lane MD. Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem 1995;64:345-373
18. van Vlijmen BJ, Rohlmann A, Page ST, et al. An extrahepatic receptor-associated protein-sensitive mechanism is involved in the metabolism of triglyceride-rich lipoproteins. J Biol Chem 1999;274:35219-35226
19. Lara-Castro C, Fu Y, Chung BH, et al. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007;18:263-270
20. Ushiroyama T, Ikeda A, Higashio S, et al. Elevated plasma leptin levels associated with high blood pressure and TG rich lipoproteins but not associated with plasma gonadotropins, estradiol and cortisol levels in pericholesterol. and postmenopausal lean women with undefined symptoms. J Med 2004;35:63-73.
21. Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:414-419
22. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-305